NYSE · DVA
DaVita Inc.
Healthcare · Medical - Care Facilities
$176.35▲ 0.82% ($1.43)at close
After hours$176.30▼ 0.03%5:35 PM ET
Market cap
Valuation
Cash-flow DCF
Verdict: cheap. Price below all scenarios.
The price holds with free cash flow shrinking 11.2% a year for 5 years. Our scenarios assume −6.6–23.4%.
That's below its past 10-year pace of 8.4%.
Value per share
Base case
$715.72
Price used $176.35 is 75% below this
USD · TTM ending Jun 30, 2026 · Price Oct 1, 8:00 PM UTC
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
2 more notes
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
This estimate is at least 3× the price used. Review the assumptions behind the gap.
Free cash flow each value needs
Free cash flow today $1.7B. The price needs $1.2B by 2036. Base case: $3.2B. At its recent pace: $3.8B. Bear to Bull: $1.4B to $8.8B.
Free cash flow today $1.7B. The price needs $1.2B by 2036. Base case: $3.2B. At its recent pace: $3.8B. Bear to Bull: $1.4B to $8.8B.
Free cash flow in 2036
today $1.7B
−$2Bless than the Base case
Value per share · Base case
$715.72
Price $176.35
75% below this
- Stage 1 growth, yrs 1–5
- 8.4%
- Stage 2 growth, yrs 6–10
- 4.6%
- Discount rate
- 6.9%
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
2 more notes
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
This estimate is at least 3× the price used. Review the assumptions behind the gap.
USD · TTM ending Jun 30, 2026 · Price Oct 1, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 32.72% over the last year. Revenue grew 6.45% over the trailing twelve months. Operating margin moved from 15.78% to 15.06%. Free cash flow grew 24.94% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 28th percentile of their historical P/FCF range.
What would invalidate this read
Operating margin is at 15.06%. Revenue grew 6.45% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure.
Market multiples
Stock splits
Every 1 shares became 2
Every 2 shares became 3
Every 3 shares became 5
Profitability & growth
Analyst consensus
10
Buy
12
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q3 FY26 · EPS est $3.55 · Revenue est $3.52B
View
Institutional Sentiment
DaVita Inc. · DVA
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.